A report card to grade Helicobacter pylori therapy
- PMID: 17669098
- DOI: 10.1111/j.1523-5378.2007.00518.x
A report card to grade Helicobacter pylori therapy
Abstract
Helicobacter pylori causes a serious bacterial infectious disease, and the expectations of therapy should reflect this fact. Increasing antibiotic resistance, especially to clarithromycin, has significantly undermined the effectiveness of legacy triple therapy consisting of a proton pump inhibitor, clarithromycin, and amoxicillin. Current cure rates are consistently below 80% intention-to-treat, the accepted threshold separating acceptable from unacceptable treatment results. Grading clinical studies into effectiveness categories using prespecified criteria would allow clinicians to objectively identify and compare regimens. We offer a therapy report card similar to that used to grade the performance of school children. The intention-to-treat cure rate categories are: F or unacceptable ( 80%), D or poor (81-84%), C or fair (85-89%), B or good (90-95%), and A or excellent (95-100%). The category of "excellent" is based on the cure rates expected with other prevalent bacterial infectious diseases. We propose that only therapies that score "excellent" (grade = A) should be prescribed. Regimens scoring as B or "good" can be used if "excellent" results are not obtainable. In most regions legacy triple therapy should be abandoned as unacceptable. Quadruple therapy and sequential therapy are reasonable alternatives for initial therapy.
Similar articles
-
Helicobacter pylori treatment: is sequential or quadruple therapy the answer?Rev Gastroenterol Disord. 2008 Spring;8(2):77-82. Rev Gastroenterol Disord. 2008. PMID: 18641590 Review.
-
Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond.Drugs. 2008;68(6):725-36. doi: 10.2165/00003495-200868060-00001. Drugs. 2008. PMID: 18416582
-
Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.Helicobacter. 2009 Apr;14(2):91-9. doi: 10.1111/j.1523-5378.2009.00664.x. Helicobacter. 2009. PMID: 19298336 Clinical Trial.
-
Treatment of Helicobacter pylori.Helicobacter. 2007 Oct;12 Suppl 1:31-7. doi: 10.1111/j.1523-5378.2007.00538.x. Helicobacter. 2007. PMID: 17727458 Review.
-
Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.Helicobacter. 2008 Dec;13(6):542-9. doi: 10.1111/j.1523-5378.2008.00648.x. Helicobacter. 2008. PMID: 19166420 Clinical Trial.
Cited by
-
Leptin, CD4(+) T(reg) and the prospects for vaccination against H. pylori infection.Front Immunol. 2012 Oct 15;3:316. doi: 10.3389/fimmu.2012.00316. eCollection 2012. Front Immunol. 2012. PMID: 23087691 Free PMC article.
-
Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management.United European Gastroenterol J. 2023 Feb;11(1):103-113. doi: 10.1002/ueg2.12348. Epub 2022 Dec 23. United European Gastroenterol J. 2023. PMID: 36565017 Free PMC article.
-
Comparison of metronidazole versus clarithromycin in first-line vonoprazan-based triple therapy for Helicobacter pylori: A multicenter randomized trial in Japan.JGH Open. 2024 Apr 22;8(4):e13069. doi: 10.1002/jgh3.13069. eCollection 2024 Apr. JGH Open. 2024. PMID: 38650971 Free PMC article.
-
Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.BMC Gastroenterol. 2015 Dec 3;15:170. doi: 10.1186/s12876-015-0401-4. BMC Gastroenterol. 2015. PMID: 26635102 Free PMC article.
-
Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial.Trials. 2017 Nov 17;18(1):549. doi: 10.1186/s13063-017-2281-0. Trials. 2017. PMID: 29149904 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical